Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Gregory Lucier Joins RainTree Oncology Board Of Directors



          Gregory Lucier Joins RainTree Oncology Board Of Directors

PR Newswire

SAN DIEGO, Sept. 23, 2013

SAN DIEGO, Sept. 23, 2013 /PRNewswire/ -- RT Oncology Services Corporation
today announced that it has elected Gregory T. Lucier to its board of
directors. Lucier is the chairman of the board and chief executive officer of
Life Technologies Corporation.

RainTree Oncology and Life Technologies recently announced a collaboration
designed to advance personalized care for cancer patients. RainTree Oncology
is actively building an infrastruction of collaborators from throughout the
industry to support its nationwide network of approximately 800 total
physicians, the majority of which are medical oncologists, in approaching 50
practices.

"Greg has applied his more than 25 years of strategic management at Life
Technologies to shaping an era of personalized medicine, while building a
company known for excellence in its products and breakthrough discoveries,"
said Mike Martin, RainTree Oncology president and chief executive officer.
"His knowledge, relationships and guidance will be of great value as we
continue to execute our vision of revolutionizing community oncology practice
performance and patient care."

"RainTree Oncology and Life Technologies share a commitment to making cancer a
manageable, treatable disease," said Lucier. "It is a privilege to contribute
to the fine work that RainTree is doing on the front of elevating cancer care
in the community setting, where most patients are treated."

Lucier has been chairman of the board and chief executive officer of Life
Technologies since 2003. With a presence in more than 180 countries, the
company's portfolio of 50,000 end-to-end solutions is secured by more than
5,000 patents and licenses that span the entire biological spectrum—scientific
exploration, molecular diagnostics, 21st century forensics, regenerative
medicine and agricultural research.

Lucier is chairman of the board at Sanford-Burnham Institute and also serves
on the boards of CareFusion Corporation, a New York Stock Exchange Company,
Synthetic Genomics Inc., and Rady Children's Hospital.

About RainTree Oncology Services
RainTree Oncology Services is the nation's leading community oncology
alliance, assisting its member practices in achieving better and more
cost-effective treatment of oncology patients while creating new streams of
revenue for community oncology practices. RainTree Oncology achieves this by
negotiating and administering favorable GPO contracts; by implementing
technology allowing RainTree Oncology members to develop and evaluate care
pathways to improve patient care and outcomes while reducing costs to the
healthcare system; and by developing commercial relationships that accelerate
innovative oncology treatments and payer arrangements while optimizing
oncology patient care and advancing the science of oncology. For more
information about RainTree Oncology Services visit www.raintreeoncology.com.

SOURCE RainTree Oncology Services

Website: http://www.raintreeoncology.com
Contact: Company, Mike Martin, President & CEO, 858.436.7450,
mmartin@raintreeoncology.com; or Media, Nadine Padilla, LawPadilla
Communications, 619.507.9306, nadine@lawpadilla.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement